ProQR Therapeutics NV
NASDAQ:PRQR
ProQR Therapeutics NV
NASDAQ:PRQR
Price:
1.8
USD
-2.7%
Market Closed
Market Cap:
$189.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
NL |
|
POCO Holding Co Ltd
SZSE:300811
|
CN |
|
Chongqing Construction Engineering Group Co Ltd
SSE:600939
|
CN |
|
D
|
Daesang Corp
KRX:001680
|
KR |
|
M
|
Materials Petroleum JSC
VN:COM
|
VN |
|
Indigo Books and Music Inc
TSX:IDG
|
CA |
|
Pegasus Sewing Machine Mfg Co Ltd
TSE:6262
|
JP |
|
Bunzl plc
LSE:BNZL
|
UK |
|
Best Agrolife Ltd
NSE:BESTAGRO
|
IN |
|
Shihlin Paper Corp
TWSE:1903
|
TW |
|
Alico Inc
NASDAQ:ALCO
|
US |
|
C
|
CJ Seafood Corp
KRX:011150
|
KR |
|
B
|
Bsm Chemical Co Ltd
SZSE:300796
|
CN |
|
Morris State Bancshares Inc
OTC:MBLU
|
US |
|
Dogan Burda Dergi Yayincilik ve Pazarlama AS
IST:DOBUR.E
|
TR |
Multiples-Based Value
The
Multiples-Based Value for
ProQR Therapeutics NV (PRQR)
under the Base Case is
hidden
USD.
Compared with the current market price of 1.8 USD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PRQR Multiples-Based Value
LOCKED
Multiples Across Competitors
PRQR Competitors Multiples
ProQR Therapeutics NV Competitors
ProQR Therapeutics NV Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NL |
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
199.3m USD | 10.3 | -4 | -2.1 | -2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365B USD | 6 | 87.2 | 14.5 | 20.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.6B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.5B USD | 5.9 | 20.3 | 12.7 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 9.3 | 28.3 | 21.2 | 22.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.5 | 13 | 14.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 11.8 | 37.9 | 40.9 | 41.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 2.9 | 32.4 | 10.9 | 13.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
